Glitazone use associated with reduced risk of Parkinson's disease.
Glitazone use associated with reduced risk of Parkinson's disease.
复制标题
DOI：
10.1002/mds.27128
复制
发表时间：
2017-11
期刊：
影响因子：
--
通讯作者：
Tzoulis C
中科院分区：
文献类型：
--
作者：
Brakedal B;Flønes I;Reiter SF;Torkildsen Ø;Dölle C;Assmus J;Haugarvoll K;Tzoulis C
抗糖尿病药物格列酮是否可以预防帕金森病仍然存在争议。虽然一项临床试验没有显示疾病调节的证据，但回顾性研究表明疾病预防效果可能是合理的。本研究的目的是检查格列酮药物的使用是否与糖尿病患者PD发生率降低相关。我们比较了在挪威处方数据库中使用格列酮（联合或不联合二甲双胍）的糖尿病患者与仅使用二甲双胍的患者之间PD的发生率。该数据库包含为整个挪威人口配发的所有处方药。我们在10年期间确定了94，349名二甲双胍使用者和8396名格列酮使用者，并使用考克斯回归生存分析比较了两组的PD发生率，格列酮暴露作为时间依赖性协变量。与仅使用二甲双胍相比，使用格列酮可显著降低PD发生率（风险比，0.72; 95%置信区间，0.55 - 0.94; P = 0.01）。格列酮的使用与糖尿病人群中PD事件风险降低相关。需要进一步的研究来证实和了解格列酮在神经退行性变中的作用。© 2017作者。出版社：Wiley Periodicals，Inc.国际帕金森和运动障碍协会（International Parkinson and Movement Disorder Society）
Whether antidiabetic glitazone drugs protect against Parkinson's disease remains controversial. Although a single clinical trial showed no evidence of disease modulation, retrospective studies suggest that a disease‐preventing effect may be plausible. The objective of this study was to examine if the use of glitazone drugs is associated with a lower incidence of PD among diabetic patients. We compared the incidence of PD between individuals with diabetes who used glitazones, with or without metformin, and individuals using only metformin in the Norwegian Prescription Database. This database contains all prescription drugs dispensed for the entire Norwegian population. We identified 94,349 metformin users and 8396 glitazone users during a 10‐year period and compared the incidence of PD in the 2 groups using Cox regression survival analysis, with glitazone exposure as a time‐dependent covariate. Glitazone use was associated with a significantly lower incidence of PD compared with metformin‐only use (hazard ratio, 0.72; 95% confidence interval, 0.55‐0.94; P = 0.01). The use of glitazones is associated with a decreased risk of incident PD in populations with diabetes. Further studies are warranted to confirm and understand the role of glitazones in neurodegeneration. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society
登录
查看更多内容
影响因子：
3.3
作者：
Carta, A. R.;Frau, L.;Carboni, E.
通讯作者：
Carboni, E.
影响因子：
16.2
作者：
Cereda E;Barichella M;Pedrolli C;Klersy C;Cassani E;Caccialanza R;Pezzoli G
通讯作者：
Pezzoli G
影响因子：
3.4
作者：
Schintu, Nicoletta;Frau, Lucia;Carta, Anna R.
通讯作者：
Carta, Anna R.
影响因子：
15.8
作者：
Brauer R;Bhaskaran K;Chaturvedi N;Dexter DT;Smeeth L;Douglas I
通讯作者：
Douglas I
影响因子：
4.1
作者：
Joutsa, Juho;Gardberg, Maria;Kaasinen, Valtteri
通讯作者：
Kaasinen, Valtteri